UNSPSC 51312802: Dimetotiazine

This classification denotes a histamine h1 antagonist and phenothiazine with the molecular formula C19H25N3O2S2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 1FTA475ZDB, chemically known as 10-(2-(dimethylamino)propyl)-n,n-dimethylphenothiazine-2-sulfonamide but generally known as dimetotiazine, which bears US NIH Compound Identifier 3089. European Medicines Agency schedules Dimetotiazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07182MIG.

UNSPSC 51312802 Dimetotiazine, a Commodity code, covers pharmaceutical products and drug-related systems purchased by state and local health agencies, though recent solicitations under this code show activity primarily in naloxone procurement and broader generic pharmaceutical supply contracts rather than dimetotiazine specifically. State and local governments use this code to acquire naloxone kits, safe drug deactivation systems, and generic multi-source pharmaceuticals for community health initiatives, emergency response programs, and state health benefit plans. Issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across multiple jurisdictions and member agencies.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida posted an IFB (Solicitation Number IFB60459723LAS) on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission issued an RFI (HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative focused on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) posted an RFP (S1070000015802) on January 20, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with proposals due March 26, 2026 and contract effectiveness targeted for July 1, 2026. Vendors responding to these opportunities must comply with cGMP and drug supply chain security requirements, maintain specified insurance coverage, and accept administrative fees or performance-based pricing models.